Skip to main content
Top
Published in: Clinical Rheumatology 6/2019

01-06-2019 | Arthritis | Brief Report

Early arthritis clinic is cost-effective, improves outcomes and reduces biologic use

Author: M K Nisar

Published in: Clinical Rheumatology | Issue 6/2019

Login to get access

Abstract

There is good evidence that dedicated early arthritis clinics (EACs) improve referral lag time and reduce delay in establishing disease-modifying therapy. However, it remains arguable whether such clinics improve relevant disease outcomes. Nationally, only 57% of units have dedicated EACs. Our rheumatology department established a centralised, patient-focused and multidisciplinary EAC to achieve key financial and clinical outcome targets the department was failing to meet. The EAC aimed to increase the department’s capacity to accommodate referrals from general practitioners (GPs) and other sources, decrease the time between diagnosis and starting therapy, establish standardised treatment algorithms and reduce biologic use. The EAC was established in January 2016 and comprised the introduction of a dedicated referral pro forma and an EA educational programme for GPs, pooling of all sources of referral, running of six EACs per week with availability of ultrasound and introduction of a standardised approach to the early initiation of therapy and timely review of treatment outcomes. The introduction of the EAC was associated with improved clinical outcomes (EA patients achieving a Disease Activity Score 28 (DAS28) < 3.2 in 2015, 38.0% [N = 113] vs. 78.5% [N = 220] in 2016) and overall patient experience (mean waiting time for EA patients’ first appointment in 2015: 12 weeks vs. 2.5 weeks in 2016; 94% [N = 167] of patients recommended the rheumatology service in 2016 vs. 74% [N = 100] in 2015). The total costs associated with introducing the EAC were ~ £201,362. Use of biologics decreased from 26.0 to 5.6% between 2015 and 2016, resulting in a cost saving of ~ £394,942. Other cost savings associated with the EAC included reductions in the overall cost/patient seen (2015, £198.88; 2016, £74.98) and not running any premium rate initiative clinics (saving ~ £26,500 in 2016) to meet waiting list targets. Efficiency gains from the introduction of the EACs have improved patients’ health and overall satisfaction with their treatment, whilst saving costs for healthcare.
Literature
1.
go back to reference Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, Bakkers M, Brodin N, Burmester GR, Codreanu C, Conway R, Dougados M, Emery P, Ferraccioli G, Fonseca J, Raza K, Silva-Fernández L, Smolen JS, Skingle D, Szekanecz Z, Kvien TK, van der Helm-van Mil A, van Vollenhoven R (2017) 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 76:948–959CrossRefPubMed Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, Bakkers M, Brodin N, Burmester GR, Codreanu C, Conway R, Dougados M, Emery P, Ferraccioli G, Fonseca J, Raza K, Silva-Fernández L, Smolen JS, Skingle D, Szekanecz Z, Kvien TK, van der Helm-van Mil A, van Vollenhoven R (2017) 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 76:948–959CrossRefPubMed
5.
go back to reference Govoni M, Scire CA, Manara M et al (2013) Does early arthritis clinic organisation improve outcomes? What evidence is there? A systematic review. Clin Exp Rheumatol 31:443–451PubMed Govoni M, Scire CA, Manara M et al (2013) Does early arthritis clinic organisation improve outcomes? What evidence is there? A systematic review. Clin Exp Rheumatol 31:443–451PubMed
6.
go back to reference Walker-Bone K, Black C (2016) The importance of work participation as an outcome in rheumatology. Rheumatology (Oxford) 55:1345–1347CrossRef Walker-Bone K, Black C (2016) The importance of work participation as an outcome in rheumatology. Rheumatology (Oxford) 55:1345–1347CrossRef
7.
go back to reference March L, Lapsley H (2000) What are the costs to society and the potential benefits from the effective management of early rheumatoid arthritis? Best Pract Res Clin Rheumatol 15:171–185CrossRef March L, Lapsley H (2000) What are the costs to society and the potential benefits from the effective management of early rheumatoid arthritis? Best Pract Res Clin Rheumatol 15:171–185CrossRef
8.
go back to reference Null Dexneuner V, Rezende LS, Stamm TA, Duer M, Smolen JS, Machold KP (2012) Attending and non-attending patients in a real-life setting of an early arthritis clinic: why do people leave clinics and where do they go? Clin Exp Rheumatol 30:184–190 Null Dexneuner V, Rezende LS, Stamm TA, Duer M, Smolen JS, Machold KP (2012) Attending and non-attending patients in a real-life setting of an early arthritis clinic: why do people leave clinics and where do they go? Clin Exp Rheumatol 30:184–190
Metadata
Title
Early arthritis clinic is cost-effective, improves outcomes and reduces biologic use
Author
M K Nisar
Publication date
01-06-2019
Publisher
Springer London
Keyword
Arthritis
Published in
Clinical Rheumatology / Issue 6/2019
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04515-3

Other articles of this Issue 6/2019

Clinical Rheumatology 6/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.